Strong Performance of European High Growth Tech Companies, Genmab Reports $3.85 Billion Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Should l Buy GMAB?
Source: Yahoo Finance
- Market Resilience: The pan-European STOXX Europe 600 Index rose by 0.77%, supported by strong economic data and earnings results, indicating a cautious optimism in the market despite mixed performances among major stock indexes.
- Genmab's Innovative Partnership: Genmab's strategic alliance with Anthropic aims to integrate AI into its R&D processes, enhancing the efficiency of its antibody product clinical developments, which is expected to solidify its leading position in oncology.
- LINK Mobility's Recovery Potential: Despite a 40.4% contraction in earnings growth, LINK Mobility Group Holding is projected to achieve an annual earnings growth of 71.1%, significantly surpassing the Norwegian market's expectation of 15%, highlighting its strong recovery potential.
- Sensirion's Technological Leadership: Sensirion Holding AG excels in sensor technology with a 5.9% annual revenue growth and a forecasted 25.8% earnings growth, with innovations in environmental monitoring technology further enhancing its market competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GMAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GMAB
Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 38.50 USD with a low forecast of 26.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 30.970
Low
26.00
Averages
38.50
High
48.00
Current: 30.970
Low
26.00
Averages
38.50
High
48.00
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
- Surge in FDA Approvals: In 2025, over 50 FDA approvals were granted, with 20 in Q4 alone, indicating strong institutional confidence in late-stage platforms, which benefits Oncolytics Biotech by attracting increased investor interest.
- Leadership Enhancement: Oncolytics Biotech appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive late-stage clinical trial experience to drive complex multi-country registration trials.
- Impressive Clinical Data: In colorectal cancer patients, the combination of pelareorep and chemotherapy achieved a 33% response rate, significantly surpassing the traditional 6-11% response rate, showcasing its competitive edge and potential commercial value in the market.
- Phase 3 Trial Design Approved: Oncolytics Biotech has secured FDA approval for its Phase 3 trial design for pancreatic cancer, marking the imminent launch of its registration trial in this notoriously difficult-to-treat area, further solidifying its market position.
See More
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
- Surge in FDA Approvals: In 2025, over 50 FDA drug approvals were granted, with 20 in Q4 alone, indicating strong institutional confidence in late-stage platforms, positioning Oncolytics Biotech to benefit from increased capital inflow.
- Leadership Enhancement: Oncolytics Biotech announced the hiring of two key executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, whose extensive experience will enhance the company's execution in complex multi-country registration trials.
- Impressive Clinical Data: In colorectal cancer, pelareorep combined with chemotherapy achieved a 33% response rate, three times higher than traditional treatments, showcasing its competitive edge and likely attracting more investor interest.
- Regulatory Approval Secured: Oncolytics Biotech has received FDA approval for its Phase 3 trial design for pancreatic cancer, making it the only immunotherapy registration trial planned for this challenging disease, further solidifying its market position.
See More
Alphabet and Nvidia Lead AI Investment Wave, AbbVie and IBKR Show Long-Term Resilience
- AI Investment Opportunity: Alphabet showcases strong cash flow and market leadership with a 34% year-over-year growth in Google Cloud, making it an attractive option for patient investors looking to capitalize on AI technologies.
- Technological Edge: Nvidia revealed at CES 2026 that the revenue potential for its Blackwell and Rubin systems exceeds $500 billion, having secured over half of Taiwan Semiconductor's advanced packaging capacity, indicating robust demand and market dominance in the AI sector.
- Immunology Growth: AbbVie's Skyrizi and Rinvoq achieved year-over-year growth of 46% and 34% in Q3, respectively, with combined sales expected to reach $31 billion by 2027, demonstrating resilience and a diversified strategy post-Humira patent loss.
- Brokerage Business Expansion: Interactive Brokers reported a 21% year-over-year increase in net interest income to $967 million in Q3 2025, with client cash balances hitting $150 billion, reflecting strong performance and market expansion potential in a high-interest rate environment.
See More
2026 Investment Outlook: Four Stocks with Compounding Potential
- Google Cloud Growth: Alphabet's Google Cloud achieved a 34% year-over-year growth in Q3, with revenue reaching $15.2 billion, indicating strong demand for generative AI, which is expected to further drive overall revenue growth and solidify its market position.
- Nvidia Market Dominance: At CES 2026, Nvidia revealed that the revenue potential for its Blackwell and Rubin systems exceeds $500 billion, and it has secured over half of Taiwan Semiconductor's advanced packaging capacity, which is expected to significantly enhance its profitability and market share.
- AbbVie Immunology Growth: AbbVie's Skyrizi and Rinvoq saw year-over-year growth of 46% and 34% in Q3, respectively, with combined sales expected to reach $31 billion by 2027, demonstrating strong market performance after losing Humira's patent exclusivity.
- Interactive Brokers Client Growth: Interactive Brokers reported a 21% year-over-year increase in net interest income to $967 million in Q3 2025, with client cash balances reaching $150 billion and customer count rising to 4 million, showcasing its strong growth potential in a high-interest rate environment.
See More
Genmab's DARZALEX Sales Reach $14.35 Billion in 2025, Continuing Growth
- Sales Growth: Genmab's flagship antibody therapy DARZALEX achieved net sales of $14.35 billion in 2025, reflecting a 23.8% increase from $11.67 billion in 2024, indicating sustained global demand and market acceptance.
- U.S. Market Performance: Sales in the U.S. reached $8.27 billion in 2025, up 25.8% from $6.59 billion in 2024, showcasing the therapy's widespread application and recognition in multiple myeloma treatment.
- International Market Expansion: International sales rose from $5.08 billion in 2024 to $6.08 billion in 2025, marking a 19.7% increase, demonstrating Genmab's successful market penetration and product promotion strategies globally.
- Future Outlook: Genmab is set to report its annual results for 2025 on February 17, 2026, which is expected to further solidify its leadership position in antibody therapies and provide investors with clearer growth prospects.
See More
Genmab Reports $14.35 Billion in DARZALEX® Global Sales for 2025
- Strong Sales Performance: Genmab announced that global net sales of DARZALEX® (daratumumab) reached $14.35 billion in 2025, with $8.27 billion from the U.S. and $6.09 billion from the rest of the world, indicating robust demand and growth potential for the drug in the global market.
- Royalty Revenue: Genmab's royalties from Johnson & Johnson (J&J) on worldwide net sales reinforce its market position in the antibody drug sector and provide stable funding for future research and development initiatives.
- Market Expansion Potential: With ongoing promotion of DARZALEX® and the development of new indications, Genmab is poised to further increase its market share in the coming years, particularly in the competitive landscape of global cancer treatment.
- Innovation-Driven Growth: Genmab is committed to improving the lives of cancer patients through innovative antibody medicines and will continue to advance its strong clinical pipeline, aiming to deliver transformative therapies and enhance its influence in the biotechnology industry.
See More
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
- Surge in FDA Approvals: In 2025, over 50 FDA approvals were granted, with 20 in Q4 alone, indicating strong institutional confidence in late-stage platforms, which benefits Oncolytics Biotech by attracting increased investor interest.
- Leadership Enhancement: Oncolytics Biotech appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive late-stage clinical trial experience to drive complex multi-country registration trials.
- Impressive Clinical Data: In colorectal cancer patients, the combination of pelareorep and chemotherapy achieved a 33% response rate, significantly surpassing the traditional 6-11% response rate, showcasing its competitive edge and potential commercial value in the market.
- Phase 3 Trial Design Approved: Oncolytics Biotech has secured FDA approval for its Phase 3 trial design for pancreatic cancer, marking the imminent launch of its registration trial in this notoriously difficult-to-treat area, further solidifying its market position.
See More
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
- Surge in FDA Approvals: In 2025, over 50 FDA drug approvals were granted, with 20 in Q4 alone, indicating strong institutional confidence in late-stage platforms, positioning Oncolytics Biotech to benefit from increased capital inflow.
- Leadership Enhancement: Oncolytics Biotech announced the hiring of two key executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, whose extensive experience will enhance the company's execution in complex multi-country registration trials.
- Impressive Clinical Data: In colorectal cancer, pelareorep combined with chemotherapy achieved a 33% response rate, three times higher than traditional treatments, showcasing its competitive edge and likely attracting more investor interest.
- Regulatory Approval Secured: Oncolytics Biotech has received FDA approval for its Phase 3 trial design for pancreatic cancer, making it the only immunotherapy registration trial planned for this challenging disease, further solidifying its market position.
See More
Alphabet and Nvidia Lead AI Investment Wave, AbbVie and IBKR Show Long-Term Resilience
- AI Investment Opportunity: Alphabet showcases strong cash flow and market leadership with a 34% year-over-year growth in Google Cloud, making it an attractive option for patient investors looking to capitalize on AI technologies.
- Technological Edge: Nvidia revealed at CES 2026 that the revenue potential for its Blackwell and Rubin systems exceeds $500 billion, having secured over half of Taiwan Semiconductor's advanced packaging capacity, indicating robust demand and market dominance in the AI sector.
- Immunology Growth: AbbVie's Skyrizi and Rinvoq achieved year-over-year growth of 46% and 34% in Q3, respectively, with combined sales expected to reach $31 billion by 2027, demonstrating resilience and a diversified strategy post-Humira patent loss.
- Brokerage Business Expansion: Interactive Brokers reported a 21% year-over-year increase in net interest income to $967 million in Q3 2025, with client cash balances hitting $150 billion, reflecting strong performance and market expansion potential in a high-interest rate environment.
See More
2026 Investment Outlook: Four Stocks with Compounding Potential
- Google Cloud Growth: Alphabet's Google Cloud achieved a 34% year-over-year growth in Q3, with revenue reaching $15.2 billion, indicating strong demand for generative AI, which is expected to further drive overall revenue growth and solidify its market position.
- Nvidia Market Dominance: At CES 2026, Nvidia revealed that the revenue potential for its Blackwell and Rubin systems exceeds $500 billion, and it has secured over half of Taiwan Semiconductor's advanced packaging capacity, which is expected to significantly enhance its profitability and market share.
- AbbVie Immunology Growth: AbbVie's Skyrizi and Rinvoq saw year-over-year growth of 46% and 34% in Q3, respectively, with combined sales expected to reach $31 billion by 2027, demonstrating strong market performance after losing Humira's patent exclusivity.
- Interactive Brokers Client Growth: Interactive Brokers reported a 21% year-over-year increase in net interest income to $967 million in Q3 2025, with client cash balances reaching $150 billion and customer count rising to 4 million, showcasing its strong growth potential in a high-interest rate environment.
See More
Genmab's DARZALEX Sales Reach $14.35 Billion in 2025, Continuing Growth
- Sales Growth: Genmab's flagship antibody therapy DARZALEX achieved net sales of $14.35 billion in 2025, reflecting a 23.8% increase from $11.67 billion in 2024, indicating sustained global demand and market acceptance.
- U.S. Market Performance: Sales in the U.S. reached $8.27 billion in 2025, up 25.8% from $6.59 billion in 2024, showcasing the therapy's widespread application and recognition in multiple myeloma treatment.
- International Market Expansion: International sales rose from $5.08 billion in 2024 to $6.08 billion in 2025, marking a 19.7% increase, demonstrating Genmab's successful market penetration and product promotion strategies globally.
- Future Outlook: Genmab is set to report its annual results for 2025 on February 17, 2026, which is expected to further solidify its leadership position in antibody therapies and provide investors with clearer growth prospects.
See More
Genmab Reports $14.35 Billion in DARZALEX® Global Sales for 2025
- Strong Sales Performance: Genmab announced that global net sales of DARZALEX® (daratumumab) reached $14.35 billion in 2025, with $8.27 billion from the U.S. and $6.09 billion from the rest of the world, indicating robust demand and growth potential for the drug in the global market.
- Royalty Revenue: Genmab's royalties from Johnson & Johnson (J&J) on worldwide net sales reinforce its market position in the antibody drug sector and provide stable funding for future research and development initiatives.
- Market Expansion Potential: With ongoing promotion of DARZALEX® and the development of new indications, Genmab is poised to further increase its market share in the coming years, particularly in the competitive landscape of global cancer treatment.
- Innovation-Driven Growth: Genmab is committed to improving the lives of cancer patients through innovative antibody medicines and will continue to advance its strong clinical pipeline, aiming to deliver transformative therapies and enhance its influence in the biotechnology industry.
See More
